-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下：巴克莱银行公布了2026年第一季度稳健的业绩，税前利润为28.1亿英镑（同比增长3%），股本回报率（RoTE）为13.5%，与市场普遍预期的28.3亿英镑基本一致。总收入增长6%至81.6亿英镑，反映出各业务板块的全面增长。其中，投资银行创下季度收入新高，超过40亿英镑（全球市场业务增长6%，银行手续费收入增长17%），英国业务也持续增长，净利息收入（NII）增长12%。鉴于2026年第一季度展现出的强劲势头，我们认为巴克莱银行仍有望实现其目标。所有业务部门均实现了两位数的收益，包括美国消费者银行的股本回报率从4.5%提升至18.8%。管理层重申了2026年和2028年的所有财务目标，并表示有信心在多元化平台的支持下，分别在2026年和2028年实现超过12%和超过14%的股本回报率（RoTE）。公司资本实力依然强劲，一级资本充足率（CET1）达到14.1%，接近13%-14%的目标区间上限，这为在完成正在进行的10亿英镑股票回购计划后宣布的5亿英镑股票回购计划提供了支持。
Related Articles
International
U.S. Energy Production Climbs 3% YoY in January, EIA Reports
U.S. primary energy production rose 3% year over year in January to 9.1 quadrillion British thermal units, the U.S. Energy Information Administration said in its Monthly Energy Review released Monday.Total fossil fuels production in January was made up of 46% dry natural gas, 31% crude oil, 12% crude oil and 11% natural gas plant liquids, the EIA reported.Total renewable energy production was composed of 56% biomass, 20% wind, 12% hydroelectric power, 11% solar and 1% geothermal energy, according to the agency.U.S. natural gas plant liquids production was 7% higher in January than in the year-ago month. Dry natural gas production and renewable energy production each climbed 4%. Nuclear electric power production and coal production each increased 2%. Crude oil production rose 1%.
$CLX1$LCOX1$NGV1$UNG$UNL$USO
Asia
CanSino Biologics Widens Loss in Q1
CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.
$HKG:6185$SHA:688185
Japan